All News Orexo AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
19.9 ^SEK	-0.50%		+1.53%	+28.72%

May. 08	Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024
May. 08	Orexo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Orexo AB's sustainability work ranked among top 5% by EcoVadis	Jul. 10	AQ
Orexo: invitation to presentation of the Q2 2024 Interim Report	Jul. 08	AQ
Orexo : Presentation	Jun. 25	PU
Orexo : Life Science Investor Forum US, June 20 (Presentation)	Jun. 13	PU
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm	May. 10	AQ
Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024	May. 08
Orexo Q1 2024 Interim Report	May. 08	AQ
Orexo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Fentanyl awareness day: The synthetic opioid fentanyl increasingly poisons young Americans	May. 07	PU
Orexo : Invitation to presentation of Orexo´s Q1 2024 Interim Report	May. 02	PU
Report from Orexo AB's annual general meeting, 26 April 2024	Apr. 26	AQ
Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment	Apr. 17	MT
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US	Apr. 17	AQ
Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US	Apr. 17	CI
Sweden's Orexo Set for Early Redemption of Bonds Due 2025	Apr. 02	MT
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled	Apr. 02	AQ
Orexo publishes the Annual and Sustainability Report for 2023	Mar. 28	AQ
Orexo AB Announces Board Resignations	Mar. 22	CI
Correction: Notice of Annual General Meeting of Orexo	Mar. 15	AQ
Notice of Annual General Meeting of Orexo	Mar. 15	AQ

No results for this search